Detailed eye imaging after presbyopia‑correcting lens implantation using OCT and pyramid aberrometry

Pseudophakic Eyes Implanted With Different Presbyopia-correcting IOL Designs: 3-D Anterior Segment OCT Biometry and Pyramid Wavefront Sensing- Based Retinal Image Quality

Observational Vienna Institute for Research in Ocular Surgery · NCT07436247

This project will test whether detailed OCT and pyramid wavefront imaging can describe how well presbyopia‑correcting intraocular lenses perform in people after cataract surgery.

Quick facts

Study typeObservational
Enrollment80 (estimated)
Ages21 Years to 110 Years
SexAll
SponsorVienna Institute for Research in Ocular Surgery Academic / other
Locations2 sites (Vienna and 1 other locations)
Trial IDNCT07436247 on ClinicalTrials.gov

What this trial studies

This observational imaging study collects high-resolution anterior segment OCT biometry together with pyramidal wavefront measurements in eyes implanted with presbyopia‑correcting intraocular lenses. Investigators will correlate three‑dimensional anterior segment morphology with ocular wavefront data to characterize in vivo optical quality of pseudophakic eyes. The protocol uses spectral‑domain or swept‑source OCT and the Osiris‑T pyramidal wavefront sensor to derive internal lens aberrations and objective optical metrics. Results aim to link biometric eye models with non‑paraxial optical measurements to better understand lens performance.

Who should consider this trial

Good fit: Adults over 21 who had uncomplicated cataract or IOL‑exchange surgery, have good corrected distance visual acuity (≤0.1 logMAR), clear posterior capsule, no corneal scars or dry eye that affect light transmission, and no other significant ocular comorbidity.

Not a fit: Patients with prior corneal refractive or other ocular surgery, posterior capsule opacification, keratometry outside 42.5–45 D, corneal spherical aberration >0.4 μm, angle kappa >0.4 mm, zonular weakness, pseudoexfoliation, poor fixation (nystagmus/tremor), or pregnancy are excluded and unlikely to benefit.

Why it matters

Potential benefit: If successful, this could help surgeons choose and optimize presbyopia‑correcting IOLs to improve postoperative visual quality.

How similar studies have performed: OCT and conventional wavefront aberrometry are established methods for characterizing ocular optics, but combining high‑resolution OCT with pyramidal wavefront sensing in pseudophakic eyes is relatively novel and not widely reported.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Men and women aged above 21 years with prior uncomplicated cataract/IOL exchange surgery
2. Willing to sign informed consent before measurements
3. Corrected distance visual acuity (CDVA) of 0.1 logMAR or better
4. Absence of corneal scars/dry eye disease that could falsify the light transmission of the study eye
5. Total absence of posterior capsule opacification or patients who already have undergone Nd:YAG capsulotomy
6. Absence of ocular comorbidity (Macular degeneration, glaucoma, amblyopia)

Exclusion Criteria:

1. Prior corneal refractive or ocular surgery
2. Posterior capsule opacification.
3. Keratometry between \<42.5 and \>45 D,
4. Corneal spherical aberration \> 0.4 microns 5) Angle kappa \> 0.4 mm

6\) Zonular weakness 7) Pseudoexfoliation syndrome 8) Eccentric fixation or insufficient ability to fixate (tremor, nystagmus) 9) Pregnancy

Where this trial is running

Vienna and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions CataractIntraocular LensesPyramid wavefrontPyramid Aberrometry
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.